1. Home
  2. AVDL vs PACS Comparison

AVDL vs PACS Comparison

Compare AVDL & PACS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • PACS
  • Stock Information
  • Founded
  • AVDL 2015
  • PACS 2013
  • Country
  • AVDL Ireland
  • PACS United States
  • Employees
  • AVDL N/A
  • PACS N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • PACS
  • Sector
  • AVDL Health Care
  • PACS
  • Exchange
  • AVDL Nasdaq
  • PACS Nasdaq
  • Market Cap
  • AVDL 1.8B
  • PACS 2.1B
  • IPO Year
  • AVDL 1996
  • PACS 2024
  • Fundamental
  • Price
  • AVDL $23.50
  • PACS $10.64
  • Analyst Decision
  • AVDL Buy
  • PACS Buy
  • Analyst Count
  • AVDL 9
  • PACS 4
  • Target Price
  • AVDL $18.06
  • PACS $26.25
  • AVG Volume (30 Days)
  • AVDL 5.5M
  • PACS 622.8K
  • Earning Date
  • AVDL 11-04-2025
  • PACS 11-07-2025
  • Dividend Yield
  • AVDL N/A
  • PACS N/A
  • EPS Growth
  • AVDL N/A
  • PACS 82.80
  • EPS
  • AVDL N/A
  • PACS 0.68
  • Revenue
  • AVDL $248,517,000.00
  • PACS $3,558,953,000.00
  • Revenue This Year
  • AVDL $64.21
  • PACS $28.62
  • Revenue Next Year
  • AVDL $30.80
  • PACS $16.94
  • P/E Ratio
  • AVDL N/A
  • PACS $15.54
  • Revenue Growth
  • AVDL 79.88
  • PACS 205.08
  • 52 Week Low
  • AVDL $6.38
  • PACS $7.50
  • 52 Week High
  • AVDL $23.57
  • PACS $20.54
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 91.85
  • PACS 32.57
  • Support Level
  • AVDL $18.74
  • PACS $12.10
  • Resistance Level
  • AVDL $19.00
  • PACS $12.67
  • Average True Range (ATR)
  • AVDL 0.25
  • PACS 0.69
  • MACD
  • AVDL 0.20
  • PACS -0.20
  • Stochastic Oscillator
  • AVDL 98.80
  • PACS 9.51

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About PACS PACS Group Inc. Common Stock

PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.

Share on Social Networks: